Holen Sie sich die Stockscreener-App
6.82
3.12%
-0.22
Handel nachbörslich:
6.76
-0.06
-0.88%
Schlusskurs vom Vortag:
$7.04
Offen:
$7.21
24-Stunden-Volumen:
392.64K
Relative Volume:
1.89
Marktkapitalisierung:
$87.69M
Einnahmen:
$53.74M
Nettoeinkommen (Verlust:
$29.82M
KGV:
2.967
EPS:
2.2986
Netto-Cashflow:
$-33.54M
1W Leistung:
+45.11%
1M Leistung:
+74.87%
6M Leistung:
+253.37%
1J Leistung:
+270.65%
1-Tages-Spanne:
$6.55
$7.80
1-Wochen-Bereich:
$4.4028
$7.80
52-Wochen-Spanne:
$1.345
$7.80
Q 32 Bio Inc Stock (QTTB) Company Profile
Firmenname
Q 32 Bio Inc
Sektor
Branche
Telefon
781-999-0232
Adresse
830 WINTER STREET, WALTHAM
Compare QTTB vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QTTB
Q 32 Bio Inc
|
6.82 | 90.52M | 53.74M | 29.82M | -33.54M | 2.2986 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Q 32 Bio Inc Stock (QTTB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-02-11 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2025-02-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-11 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-12-11 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-12-11 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2024-12-11 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-10-24 | Eingeleitet | Raymond James | Strong Buy |
| 2024-09-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-17 | Eingeleitet | Guggenheim | Buy |
| 2024-05-21 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-11 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-02 | Eingeleitet | Piper Sandler | Overweight |
| 2023-07-28 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-02-22 | Bestätigt | BTIG Research | Neutral |
| 2022-02-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-02-22 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-03-02 | Eingeleitet | Stifel | Hold |
| 2020-12-14 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-08-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-25 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-03-16 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-24 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-11-01 | Eingeleitet | Oppenheimer | Perform |
| 2019-09-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Q 32 Bio Inc Aktie (QTTB) Neueste Nachrichten
Q32 Bio Hits New HighRegrowth Signals? - RTTNews
Q32 Bio, Inc. Experiences Comprehensive Evaluation Adjustment Amid Financial Landscape Changes - Markets Mojo
FY2026 Earnings Estimate for Q32 Bio Issued By HC Wainwright - MarketBeat
What is HC Wainwright’s Forecast for Q32 Bio Q1 Earnings? - Defense World
Q32 Bio Faces Governance Backlash and Rising Costs After 2025 Stock Option Repricing - TipRanks
H.C. Wainwright Maintains Buy on QTTB Q32 Bio Inc. March 2026 - Meyka
H.C. Wainwright reiterates Q32 Bio stock rating with $13 target - Investing.com UK
Q32 Bio Reports Q4 2025 Financial Results, Highlights SIGNAL-AA Trial Progress and Strong Financial Runway into 2027 - Minichart
Q32 Bio Inc. (QTTB) Reports Q4 Earnings - AlphaStreet
Q32 Bio Inc. 2025 Annual Report: Business Overview, Pipeline, Risks, and Intellectual Property Strategies - Minichart
Q32 Bio 2025 Financial Results: Q4 Net Income $57.7M, Revenue $53.7MNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Q32 Bio (NASDAQ:QTTB) Releases Quarterly Earnings Results, Beats Expectations By $4.71 EPS - MarketBeat
Q32 Bio Inc. releases fourth quarter 2025 results and issues corporate update - Traders Union
Q32 Bio 10-K: $53.7M collaboration revenue drives $29.8M net income - TradingView
Q32 Bio: Q4 Earnings Snapshot - KTVB
Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire
Q32 Bio Inc expected to post a loss of 86 cents a shareEarnings Preview - TradingView
Synopsys, Moderna, Strategy, Q32 Bio, Wolfspeed: Stocks Making The Biggest Moves Today - Stocktwits
Q32 Bio Spotlights Bempikibart AA Data Ahead, Sharpens Focus After Asset Sale at Oppenheimer Confab - Defense World
QTTB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
QTTB SEC FilingsQ32 BIO INC 10-K, 10-Q, 8-K Forms - Stock Titan
QTTB PE Ratio & Valuation, Is QTTB Overvalued - Intellectia AI
FY2025 Earnings Estimate for Q32 Bio Issued By HC Wainwright - Defense World
Insider Selling: Q32 Bio (NASDAQ:QTTB) CFO Sells 3,995 Shares of Stock - MarketBeat
Insider Selling: Q32 Bio (NASDAQ:QTTB) Insider Sells 2,815 Shares of Stock - MarketBeat
Q32 Bio (QTTB) CSO auto-sells 2,815 shares to cover tax bill - Stock Titan
FY2025 Earnings Forecast for Q32 Bio Issued By HC Wainwright - MarketBeat
FY2029 Earnings Forecast for Q32 Bio Issued By HC Wainwright - Defense World
Analysts Offer Predictions for Q32 Bio FY2029 Earnings - MarketBeat
Q32 Bio (NASDAQ:QTTB) Now Covered by Analysts at HC Wainwright - Defense World
Q32 Bio (QTTB) Price Target Increased by 32.35% to 15.30 - Nasdaq
HC Wainwright & Co. Initiates Coverage of Q32 Bio (QTTB) with Buy Recommendation - Nasdaq
H.C. Wainwright initiates Q32 Bio stock coverage with buy rating - Investing.com
QTTBQ32 BIO INC Latest Stock News & Market Updates - Stock Titan
Q32 Bio Inc. $QTTB Shares Sold by Monaco Asset Management SAM - MarketBeat
Opaleye Group reports 1.256M shares in Q32 Bio (NASDAQ: QTTB) - Stock Titan
Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight (2026-02-19) - Seeking Alpha
Point72, Steven A. Cohen disclose 9.9% stake in Q32 Bio (QTTB) - Stock Titan
Biotech Q32 Bio joins Oppenheimer health conference Feb. 25 webcast - Stock Titan
Q32 Bio Announces $10.5 Million Registered Direct Offering - TipRanks
According to the latest documents disclosed by the U.S. Securities and Exchange Commission (SEC), biotechnology company Q32 Bio Inc has officially signed an agreement to issue and sell approximately 1.7 million shares of common stock. - Bitget
Q32 Bio (NASDAQ: QTTB) raises $10.5M to fund alopecia trials - Stock Titan
Q32 Bio Launches $10.5 Million Registered Direct Offering - marketscreener.com
Q32 Bio announces $10.5 million registered direct offering - marketscreener.com
Can Q32 Bio Inc. navigate macro headwindsJuly 2025 Big Picture & Safe Swing Trade Setups - mfd.ru
Is Q32 Bio Inc. stock supported by strong cash flows2025 Sector Review & Daily Growth Stock Tips - mfd.ru
What is the fair value of Q32 Bio Inc. stock nowRate Cut & Community Trade Idea Sharing Platform - mfd.ru
Will Q32 Bio Inc. benefit from geopolitical trendsIndex Update & Stepwise Entry/Exit Trade Alerts - mfd.ru
Growth Value: Will Q32 Bio Inc stock benefit from M A2025 Top Decliners & Growth Focused Entry Point Reports - baoquankhu1.vn
Pullback Watch: Will Q32 Bio Inc benefit from geopolitical trendsTrade Risk Summary & Accurate Buy Signal Alerts - baoquankhu1.vn
Market Review: Will Q32 Bio Inc benefit from geopolitical trendsWeekly Stock Recap & Community Shared Stock Ideas - baoquankhu1.vn
Finanzdaten der Q 32 Bio Inc-Aktie (QTTB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):